サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1726176

米国のインターベンショナル腫瘍学市場規模、シェア、動向分析レポート：手技別、施術別、用途別、最終用途別、セグメント予測、2025年～2030年

U.S. Interventional Oncology Market Size, Share & Trends Analysis Report By Technique (Ablation Therapies, Embolization Therapies), By Procedure (Tumor Ablation, Tumor Biopsy), By Application, By End Use, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 125 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.36円
米国のインターベンショナル腫瘍学市場規模、シェア、動向分析レポート：手技別、施術別、用途別、最終用途別、セグメント予測、2025年～2030年
出版日: 2025年04月08日
発行: Grand View Research
ページ情報: 英文 125 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

米国のインターベンショナル腫瘍学市場動向

米国のインターベンショナル腫瘍学市場規模は2024年に9億9,840万米ドルと推定され、2025～2030年にかけてCAGR 8.17％で成長すると予測されています。

同市場は、がん罹患率の増加、低侵襲手技の技術的進歩の高まり、インターベンショナル腫瘍学セグメントへの投資の増加、同国における高齢者の増加により成長しています。

米国におけるがん有病率の上昇は、市場成長を促進する主要因です。米国がん協会によると、米国における新規がん罹患者数は204万1,910人です。米国では2025年に204万1,910人が新たにがんに罹患すると推定され、同年には61万8,120人ががんで死亡すると予測されています。化学療法や放射線療法のような伝統的治療はしばしば重大な副作用を伴うので、高周波焼灼術やマイクロ波焼灼術のような低侵襲の代替療法が人気を集めています。これらの処置は、周辺組織への最小限のダメージで局所的な腫瘍破壊を提供し、患者の転帰を改善し、インターベンショナル腫瘍学ソリューションの需要を促進しています。

インターベンショナル腫瘍学の継続的な技術進歩は、これらの手技の効果と採用を強化しています。この市場に参入している企業は、先進的な製品を市場に投入するための技術革新に注力しており、それによって患者の転帰を改善しています。例えば、Profound Medicalは2023年9月、前立腺の特定部位の切除温度を一時的に上昇させるTULSA-PRO Thermal Boostモジュールについて米国FDAから510（k）認可を取得しました。このThermal Boost機能により、前立腺がん症例の88%で治療成績が向上し、治療効果とワークフロー効率の両方が改善されました。このような進歩は臨床転帰を改善し、医療提供者の間でインターベンショナル腫瘍学の魅力を高めています。

米国では、官民双方からのインターベンショナル腫瘍学への投資が拡大しており、市場の拡大が加速しています。開発、研究開発、ベンチャーキャピタルからの投資は、高精度腫瘍学を向上させる革新的な治療法の開発を支援しており、インターベンショナル技術が主流のがん治療に組み込まれることを確実にしています。例えば、2024年12月、インターベンショナルラジオロジー学会（SIR）財団は、4つの研究プロジェクトに150万米ドルの助成金を授与しました。1つは肝細胞がん（HCC）の新しいモデルを開発する研究であり、もう1つはHCCに対する精密誘導インターベンショナルのために遺伝子サブタイピングを利用する研究です。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 米国のインターベンショナル腫瘍学市場の変数、動向、範囲

  • 市場系統の展望
    • 親市場の展望
    • 関連/補助的な市場展望
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • インターベンショナル腫瘍学市場分析ツール
    • 産業分析-ポーターのファイブフォース分析
    • PESTEL分析

第4章 米国のインターベンショナル腫瘍学市場：手技別、推定・動向分析

  • セグメントダッシュボード
  • 米国のインターベンショナル腫瘍学市場の手技変動分析
  • 米国のインターベンショナル腫瘍学市場規模と動向分析（手技別、2018～2030年）
  • アブレーション療法
    • 高周波アブレーション（RFA）
    • マイクロ波アブレーション（MWA）
    • 凍結療法
    • レーザーアブレーション
    • 不可逆的電気穿孔法（IRE）
  • 塞栓療法
    • 経動脈化学塞栓術（TACE）
    • 経動脈的放射線塞栓術（TARE）
  • 生検技術
    • コア針生検
    • 細針吸引法（FNA）
  • 標的治療デリバリーシステム
    • 薬剤溶出ビーズ
    • 放射線塞栓術
    • 薬剤溶出ステント
    • 注射なハイドロゲルとナノ粒子
    • その他の標的治療システム
  • 画像誘導手術
    • 超音波ガイダンス
    • CTスキャンガイダンス
    • MRIガイダンス
    • 透視ガイダンス

第5章 米国のインターベンショナル腫瘍学市場：施術別、推定・動向分析

  • セグメントダッシュボード
  • 米国のインターベンショナル腫瘍学市場の施術変動分析
  • 米国のインターベンショナル腫瘍学市場規模と動向分析（施術別、2018～2030年）
  • 腫瘍アブレーション
  • 腫瘍生検
  • 血管インターベンショナル
  • 緩和ケア

第6章 米国のインターベンショナル腫瘍学材料市場：用途別、推定・動向分析

  • セグメントダッシュボード
  • 米国のインターベンショナル腫瘍学市場の用途変動分析
  • 米国のインターベンショナル腫瘍学市場規模と動向分析（用途別、2018～2030年）
  • 肝臓がん
  • 肺がん
  • 腎臓がん
  • 前立腺がん
  • 乳がん
  • その他のがん

第7章 米国のインターベンショナル腫瘍学市場：最終用途別、推定・動向分析

  • セグメントダッシュボード
  • 米国のインターベンショナル腫瘍学市場の最終用途変動分析
  • 米国のインターベンショナル腫瘍学市場規模と動向分析（最終用途別、2018～2030年）
  • 病院
  • 専門クリニック
  • その他

第8章 競合情勢

  • 企業/競合の分類
  • 戦略マッピング
  • 企業市況分析、2024年
  • 企業プロファイル/上場企業
    • Medtronic
    • Boston Scientific Corporation
    • Johnson & Johnson（Ethicon）
    • Cook Medical
    • AngioDynamics Inc.
    • Stryker
    • Terumo Corporation
    • Siemens Healthineers（Varian）
    • Teleflex Incorporated
    • Profound Medical
図表

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 U.S. interventional oncology market by modality, 2018 - 2030 (USD Million)
  • Table 4 U.S. interventional oncology market by technology, 2018 - 2030 (USD Million)
  • Table 5 U.S interventional oncology market by mobility, 2018 - 2030 (USD Million)
  • Table 6 U.S interventional oncology market by end use, 2018 - 2030 (USD Million)
  • Table 7 Participant's overview
  • Table 8 Financial performance
  • Table 9 Key companies undergoing expansions
  • Table 10 Key companies undergoing acquisitions
  • Table 11 Key companies undergoing collaborations
  • Table 12 Key companies launching new products
  • Table 13 Key companies undergoing partnerships
  • Table 14 Key companies undertaking other strategies

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Market formulation & validation
  • Fig. 4 U.S. interventional oncology market: Market outlook
  • Fig. 5 U.S. interventional oncology market: Segment outlook
  • Fig. 6 U.S. interventional oncology market: Competitive landscape outlook
  • Fig. 7 Parent market outlook
  • Fig. 8 U.S. interventional oncology market driver impact
  • Fig. 9 U.S. interventional oncology market restraint impact
  • Fig. 10 U.S. interventional oncology market: Technique outlook and key takeaways
  • Fig. 11 U.S. interventional oncology market: Technique movement analysis
  • Fig. 12 Ablation therapies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 13 Radiofrequency Ablation (RFA) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 14 Microwave Ablation (MWA) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 15 Cryoablation market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 16 Laser Ablation market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 17 Irreversible Electroporation (IRE) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 18 Embolization therapies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 Transarterial Chemoembolization (TACE) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Transarterial Radioembolization (TARE) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Biopsy rechniques market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Core needle biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Fine Needle Aspiration (FNA) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Targeted therapy delivery systems market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Drug-eluting beads market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Radioembolization market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Drug-eluting stents market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Injectable Hydrogels and Nanoparticles market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Other targeted therapy systems market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Image-guided procedures market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 ultrasound guidance market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 CT scan guidance market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 MRI guidance market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Fluoroscopy Guidance market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 U.S. interventional oncology market: Procedures outlook and key takeaways
  • Fig. 36 U.S. interventional oncology market: Procedures movement analysis
  • Fig. 37 Tumor ablation market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Tumor biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Vascular interventions market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Palliative care market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 U.S. interventional oncology market: Applications outlook and key takeaways
  • Fig. 42 U.S. interventional oncology market: Applications movement analysis
  • Fig. 43 Liver cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Lung cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Kidney cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Breast cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Other cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 U.S. interventional oncology market: End-use outlook and key takeaways
  • Fig. 50 U.S. interventional oncology market: End-use movement analysis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Hospitals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Specialty clinics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Other market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Heat map analysis
  • Fig. 56 Market participant categorization
  • Fig. 57 U.S. interventional oncology market share analysis, 2024
  • Fig. 58 Strategy framework
目次
Product Code: GVR-4-68040-550-1

U.S. Interventional Oncology Market Trends:

The U.S. interventional oncology market size was estimated at USD 998.4 million in 2024 and is projected to grow at a CAGR of 8.17% from 2025 to 2030. The market is growing due to increasing cancer prevalence, rising technological advancements in minimally invasive procedures, increasing investments in the field of interventional oncology, and the growing geriatric population in the country.

The rising prevalence of cancer in the U.S. is a major factor driving the market growth. According to the American Cancer Society, around. 2,041,910 new cancers are estimated to occur in the U.S. in 2025, while cancer is expected to cause 618,120 mortalities in the same year. As traditional treatments such as chemotherapy and radiation therapy often have significant side effects, minimally invasive alternatives such as radiofrequency ablation and microwave ablation are gaining popularity. These procedures offer localized tumor destruction with minimal damage to surrounding tissues, improving patient outcomes and driving demand for interventional oncology solutions.

Continuous technological advancements in interventional oncology are enhancing the effectiveness and adoption of these procedures. Companies operating in the market are focusing on innovation to introduce advanced products in the market, thereby improving patient outcomes. For instance, in September 2023, Profound Medical obtained 510(k) clearance from the U.S. FDA for its TULSA-PRO Thermal Boost module, which allows surgeons to temporarily elevate ablation temperatures in specific areas of the prostate. The Thermal Boost feature has led to improved treatment results in 88% of prostate cancer cases, thereby enhancing both efficacy and workflow efficiency. Such advancements improve clinical outcomes and increase the appeal of interventional oncology among healthcare providers.

The growing investment in interventional oncology from both public and private sectors is accelerating market expansion in the U.S. Government initiatives, research funding, and venture capital investments are supporting the development of innovative treatment modalities to improve precision oncology, ensuring that interventional techniques are integrated into mainstream cancer care. For instance, in December 2024, the Society of Interventional Radiology (SIR) Foundation awarded USD 1.5 million in grants to four research projects, two of which focus on interventional oncology. One study will develop a novel model of hepatocellular carcinoma (HCC), and the other will use genetic subtyping for precision-guided interventions for HCC.

U.S. Interventional Oncology Market Report Segmentation

This report forecasts revenue growth at country levels and analyzes the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. interventional oncology market report based on techniques, procedures, application, end use:

  • Technique Outlook (Revenue, USD Million, 2018 - 2030)
  • Ablation Therapies
    • Radiofrequency Ablation (RFA)
    • Microwave Ablation (MWA)
    • Cryoablation
    • Laser Ablation
    • Irreversible Electroporation (IRE)
  • Embolization Therapies
    • Transarterial Chemoembolization (TACE)
    • Transarterial Radioembolization (TARE)
  • Biopsy Techniques
    • Core Needle Biopsy
    • Fine Needle Aspiration (FNA)
  • Targeted Therapy Delivery Systems
    • Drug-Eluting Beads
    • Radioembolization
    • Drug-Eluting Stents
    • Injectable Hydrogels and Nanoparticles
    • Other Targeted Therapy Systems
  • Image-Guided Procedures
    • Ultrasound Guidance
    • CT Scan Guidance
    • MRI Guidance
    • Fluoroscopy Guidance
  • Procedure Outlook (Revenue, USD Million, 2018 - 2030)
  • Tumor Ablation
  • Tumor Biopsy
  • Vascular Interventions
  • Palliative Care
  • Application Outlook (Revenue, USD Million, 2018 - 2030)
  • Liver Cancer
  • Lung Cancer
  • Kidney Cancer
  • Prostate Cancer
  • Breast Cancer
  • Other Cancer
  • End-use Outlook (Revenue, USD Million, 2018 - 2030)
  • Hospitals
  • Specialty Clinics
  • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
    • 1.2.1. Technique Segment
    • 1.2.2. Procedure Segment
    • 1.2.3. Application Segment
    • 1.2.4. End-use Segment
  • 1.3. Information analysis
    • 1.3.1. Market formulation & data visualization
  • 1.4. Data validation & publishing
  • 1.5. Information Procurement
    • 1.5.1. Primary Research
  • 1.6. Information or Data Analysis
  • 1.7. Market Formulation & Validation
  • 1.8. Market Model
  • 1.9. Total Market: CAGR Calculation
  • 1.10. Objectives
    • 1.10.1. Objective 1
    • 1.10.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Insights Landscape

Chapter 3. U.S. Interventional Oncology Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of cancer
      • 3.2.1.2. Increasing technological advancements in minimally invasive procedures
      • 3.2.1.3. Growing geriatric population
      • 3.2.1.4. Increasing investments in the field of interventional oncology
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost associated with interventional oncology
      • 3.2.2.2. Requirement of highly skilled professionals
  • 3.3. Interventional Oncology Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. U.S. Interventional Oncology Market: Technique Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Interventional Oncology Market Technique Movement Analysis
  • 4.3. U.S. Interventional Oncology Market Size & Trend Analysis, by Technique, 2018 to 2030 (USD Million)
  • 4.4. Ablation Therapies
    • 4.4.1. Ablation Therapies market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.2. Radiofrequency Ablation (RFA)
      • 4.4.2.1. Radiofrequency Ablation (RFA) market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.3. Microwave Ablation (MWA)
      • 4.4.3.1. Microwave Ablation (MWA) market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.4. Cryoablation
      • 4.4.4.1. Cryoablation market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.5. Laser Ablation
      • 4.4.5.1. Laser Ablation market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.4.6. Irreversible Electroporation (IRE)
      • 4.4.6.1. Irreversible Electroporation (IRE) market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Embolization Therapies
    • 4.5.1. Embolization Therapies market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.5.2. Transarterial Chemoembolization (TACE)
      • 4.5.2.1. Transarterial Chemoembolzation (TACE) market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.5.3. Transarterial Radioembolization (TARE)
      • 4.5.3.1. Transarterial Radioembolization (TARE) market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.6. Biopsy Techniques
    • 4.6.1. Biopsy Techniques market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.6.2. Core Needle Biopsy
      • 4.6.2.1. Core Needle Biopsy market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.6.3. Fine Needle Aspiration (FNA)
      • 4.6.3.1. Fine Needle Aspiration (FNA) market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.7. Targeted Therapy Delivery Systems
    • 4.7.1. Drug Delivery Systems market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.7.2. Drug-Eluting Beads
      • 4.7.2.1. Drug-Eluting Beads market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.7.3. Radioembolization
      • 4.7.3.1. Radioembolization market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.7.4. Drug-Eluting Stents
      • 4.7.4.1. Drug-Eluting Stents market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.7.5. Injectable Hydrogels and Nanoparticles
      • 4.7.5.1. Injectable Hydrogels and Nanoparticles market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.7.6. Other Targeted Therapy Systems
      • 4.7.6.1. Other Targeted Therapy Systems market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.8. Image-Guided Procedures
    • 4.8.1. Image-Guided Procedures market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.8.2. Ultrasound Guidance
      • 4.8.2.1. Ultrasound Guidance market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.8.3. CT Scan Guidance
      • 4.8.3.1. CT Scan Guidance market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.8.4. MRI Guidance
      • 4.8.4.1. MRI Guidance market estimates and forecasts, 2018 to 2030 (USD Million)
    • 4.8.5. Fluoroscopy Guidance
      • 4.8.5.1. Fluoroscopy Guidance market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. U.S. Interventional Oncology Market: Procedures Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. Interventional Oncology Market Procedures Movement Analysis
  • 5.3. U.S. Interventional Oncology Market Size & Trend Analysis, by Procedures, 2018 to 2030 (USD Million)
  • 5.4. Tumor Ablation
    • 5.4.1. Tumor Ablation market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Tumor Biopsy
    • 5.5.1. Tumor Biopsy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.6. Vascular Interventions
    • 5.6.1. Vascular Interventions market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.7. Palliative Care
    • 5.7.1. Palliative Care market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. U.S. Interventional Oncology Materials Market: Applications Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. U.S. Interventional Oncology Market Applications Movement Analysis
  • 6.3. U.S. Interventional Oncology Market Size & Trend Analysis, by Applications, 2018 to 2030 (USD Million)
  • 6.4. Liver Cancer
    • 6.4.1. Liver Cancer market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.5. Lung Cancer
    • 6.5.1. Lung Cancer market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.6. Kidney Cancer
    • 6.6.1. Kidney Cancer market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.7. Prostate Cancer
    • 6.7.1. Prostate Cancer market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.8. Breast Cancer
    • 6.8.1. Breast Cancer market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.9. Other Cancer
    • 6.9.1. Other Cancer market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. U.S. Interventional Oncology Market: End-use Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. U.S. Interventional Oncology Market End Use Movement Analysis
  • 7.3. U.S. Interventional Oncology Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 7.4. Hospitals
    • 7.4.1. Hospitals market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5. Specialty Clinics
    • 7.5.1. Specialty Clinics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6. Others
    • 7.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company/Competition Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Market Position Analysis, 2024
  • 8.4. Company Profiles/Listing
    • 8.4.1. Medtronic
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Boston Scientific Corporation
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Johnson & Johnson (Ethicon)
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Cook Medical
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. AngioDynamics Inc.
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Stryker
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Terumo Corporation
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. Siemens Healthineers (Varian)
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. Teleflex Incorporated
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. Profound Medical
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives